NRD
DAWN

Nebula Research & Development’s Day One Biopharmaceuticals DAWN Stock Holding History

Nebula Research & Development’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,665
Closed -$394K – 248
2025
Q2 		$394K Buy
60,665
+3,533
+6% +$24.3K 0.03% 704
2025
Q1 		$453K Buy
57,132
+37,328
+188% +$402K 0.04% 638
2024
Q4 		$251K Buy
19,804
+9,697
+96% +$135K 0.03% 754
2024
Q3 		$141K Buy
+10,107
New +$144K 0.02% 858
2024
Q2 		– Sell
-19,419
Closed -$321K – 847
2024
Q1 		$321K Buy
+19,419
New +$291K 0.07% 507
2023
Q3 		– Sell
-12,380
Closed -$148K – 533
2023
Q2 		$148K Buy
+12,380
New +$162K 0.11% 286

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nebula Research & Development's DAWN Position: Q3 2025 in Review

Nebula Research & Development sold out of Day One Biopharmaceuticals (DAWN) in Q3 2025, closing a stake of 60,665 shares — an estimated $394K sold.

Nebula Research & Development first reported a position in DAWN in Q2 2023 and held it in 6 quarters. The position peaked at $453K in Q1 2025. 172 funds tracked by Wall St. Rank hold DAWN as of Q3 2025.

  • Nebula Research & Development reported no remaining Day One Biopharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 60,665 Day One Biopharmaceuticals shares in Q3 2025, an estimated $394K.
  • Nebula Research & Development first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Nebula Research & Development's Day One Biopharmaceuticals position peaked at $453K in Q1 2025.
  • 172 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.